- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Praxis Precision Medicines Inc (PRAX)
Praxis Precision Medicines Inc stock price live, this page displays NASDAQ PRAX stock exchange data. View the PRAX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Praxis Precision Medicines Inc real time stock price chart below.
What Is the Praxis Precision Medicines Inc Stock Price Today?
The Praxis Precision Medicines Inc stock price today is 48.23.
What Is the Stock Symbol for Praxis Precision Medicines Inc?
The stock symbol for Praxis Precision Medicines Inc is ""PRAX.""
What Stock Exchange Does Praxis Precision Medicines Inc Trade On?
Praxis Precision Medicines Inc is listed and trades on the NASDAQ stock exchange.
Is Praxis Precision Medicines Inc a Good Stock to Buy?
Determining whether Praxis Precision Medicines Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRAX quote. (ISIN: US74006W2070)
What Is the Praxis Precision Medicines Inc Stock Price Today?
The Praxis Precision Medicines Inc stock price today is 48.23.
What Is the Stock Symbol for Praxis Precision Medicines Inc?
The stock symbol for Praxis Precision Medicines Inc is ""PRAX.""
What Stock Exchange Does Praxis Precision Medicines Inc Trade On?
Praxis Precision Medicines Inc is listed and trades on the NASDAQ stock exchange.
Is Praxis Precision Medicines Inc a Good Stock to Buy?
Determining whether Praxis Precision Medicines Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRAX quote. (ISIN: US74006W2070)
NASDAQ
Currency in USD
48.23
+0.44(+0.92%)
Real-time Data·
Fair Value
An estimate of a Praxis Precision's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.16
49.12
52 wk Range
26.70
91.83
PRAX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PRAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Praxis Precision's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.1649.12
52 wk Range
26.7091.83
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PRAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Praxis Precision's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
99.58
Upside
+106.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Praxis Precision Medicines Inc Company Profile
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Compare PRAX to Peers and Sector
Metrics to compare | PRAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −1.1x | −0.5x | |
PEG Ratio | 0.15 | −0.06 | 0.00 | |
Price/Book | 2.5x | 2.3x | 2.6x | |
Price / LTM Sales | 129.5x | 9.9x | 3.3x | |
Upside (Analyst Target) | 72.6% | 300.9% | 42.8% | |
Fair Value Upside | Unlock | 23.8% | 6.5% | Unlock |
Analyst Ratings
11 Buy
0 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 99.58
(+106.48% Upside)
Earnings
Latest Release
Aug 04, 2025
EPS / Forecast
-3.31 / -3.25
Revenue / Forecast
-- / 209.51K
People Also Watch
FAQ
What Stock Exchange Does Praxis Precision Trade On?
Praxis Precision is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Praxis Precision?
The stock symbol for Praxis Precision is "PRAX."
What Is the Praxis Precision Market Cap?
As of today, Praxis Precision market cap is 1.01B.
What Is Praxis Precision's Earnings Per Share (TTM)?
The Praxis Precision EPS (TTM) is -12.33.
When Is the Next Praxis Precision Earnings Date?
Praxis Precision will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is PRAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Praxis Precision Stock Split?
Praxis Precision has split 1 times.
How Many Employees Does Praxis Precision Have?
Praxis Precision has 116 employees.
What is the current trading status of Praxis Precision (PRAX)?
As of 06 Aug 2025, Praxis Precision (PRAX) is trading at a price of 48.23, with a previous close of 47.79. The stock has fluctuated within a day range of 46.16 to 49.12, while its 52-week range spans from 26.70 to 91.83.
What Is Praxis Precision (PRAX) Price Target According to Analysts?
The average 12-month price target for Praxis Precision is USD99.58333, with a high estimate of USD270 and a low estimate of USD33. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +106.48% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.